( To subpage for editing >> ) SINEMET® is widely prescribed for the treatment of Parkinson's disease and some Parkinson's_Plus syndromes. Carbidopa, is an inhibitor of aromatic amino acid decarboxylation, and is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as (—)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its empirical formula is C10H14N2O4•H2O. Levodopa, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (—)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its empirical formula is C9H11NO4. Hydroxypropyl cellulose Pregelatinized starch Crospovidone Microcrystalline cellulose Magnesium stearate SINEMET 10-100 and 25-250 Tablets also contain:- FD&C Blue #2/lndigo Carmine AL. SINEMET 25-100 Tablets also contain:- D&C Yellow #10 Lake. Dyskinesia Nausea Body as a Whole Chest pain, asthenia. Cardiovascular Cardiac irregularities, hypotension, orthostatic effects including orthostatic hypotension, hypertension, syncope, phlebitis, palpitation. Gastrointestinal Dark saliva, gastrointestinal bleeding, development of duodenal ulcer, anorexia, vomiting, diarrheoa, constipation, dyspepsia , dry mouth, taste alterations. Hematologic Agranulocytosis, hemolytic and non-hemolytic anemia, thrombocytopenia, leukopenia. Hypersensitivity Angioedema, urticaria, pruritus, Henoch-Schonlein purpura, bullous lesions (including pemphigus-like reactions). Musculoskeletal Back pain, shoulder pain, muscle cramps. Nervous System/Psychiatric Psychotic episodes including delusions, hallucinations, and paranoid ideation, neuroleptic malignant syndrome, bradykinetic episodes ("on-off" phenomenon), confusion, agitation, dizziness, somnolence, dream abnormalities including nightmares, insomnia, paresthesia, headache, depression with or without development of suicidal tendencies, dementia, pathological gambling, increased libido including hypersexuality, impulse control symptoms. Respiratory Dyspnea, upper respiratory infection. Skin Rash, increased sweating, alopecia, dark sweat. Urogenital Urinary tract infection, urinary frequency, dark urine. Symptomatic postural hypotension has occurred when SINEMET was added to the treatment of a patient receiving antihypertensive drugs. Severe orthostatic hypertenson can occur for patients receiving MAO inhibitors (Type A or B). There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and SINEMET. Dopamine D2 receptor antagonists (e.g. phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa. In addition, the beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by phenytoin and papaverine. Iron salts may reduce the bioavailability of levodopa and carbidopa. Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties. (1997) Block et al carried out a multi-centre trial over 5 years comparing the effects of Sinemet (immediate Release) and Sinemet CR (Controlled Release) and found favourably for the latter. Block, G,; Liss, C.; Reines, S.; Irr. I. and Nibbelink, D. AbstractEur. Neurol. 37 (1) 23 – 27 Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s Disease http://www.karger.com/Article/Abstract/117399
{'wiki_source': 'wikiversity', 'other_info': '{\'content_model\': \'wikitext\', \'language\': \'en\', \'title\': "Parkinson\'s Symptoms/Sinemet", \'type\': \'text\'}'}